Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30

Tonix Pharmaceuticals will present findings on its drug TONMYA, which was approved by the FDA on August 15, 2025, and launched in the U.S. on November 17, 2025. The presentation, titled 'Cyclobenzaprine HCl Sublingual Reduces Fibromyalgia Impact on Physical Symptoms & Functional Ability,' will take place on October 27, 2026, at the World Congress on Pain. The poster session is scheduled for 3:15-4:45 p.m. ICT, and will be presented by Errol Gould, Ph.D., Senior Vice President of Medical Affairs at Tonix Medicines.